I Ray-Coquard
Overview
Explore the profile of I Ray-Coquard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
4155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hasson S, Ray-Coquard I, Marth C, Harter P
ESMO Open
. 2023 Nov;
8(6):102052.
PMID: 37922687
No abstract available.
12.
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, et al.
Ann Oncol
. 2023 Oct;
34(12):1152-1164.
PMID: 37797734
Background: Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. Patients...
13.
Gonzalez-Martin A, Harter P, Leary A, Lorusso D, Miller R, Pothuri B, et al.
Ann Oncol
. 2023 Aug;
34(10):833-848.
PMID: 37597580
No abstract available.
14.
Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al.
Ann Oncol
. 2023 May;
34(8):681-692.
PMID: 37211045
Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based...
15.
Rousset-Jablonski C, Mekki Y, Denis A, Reynaud Q, Nove-Josserand R, Durupt S, et al.
J Cyst Fibros
. 2022 Dec;
22(3):505-514.
PMID: 36526553
Background: A higher risk of human papillomavirus (HPV)-related cervical intra-epithelial neoplasia (CIN) is suspected among females with cystic fibrosis (CF). Methods: We conducted a single center prospective cohort study among...
16.
Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F, et al.
ESMO Open
. 2022 Sep;
7(5):100579.
PMID: 36108558
Despite screening programs for early detection and the approval of human papillomavirus vaccines, around 6% of women with cervical cancer (CC) are discovered with primary metastatic disease. Moreover, one-third of...
17.
Henno S, Jeanne C, de La Motte Rouge T, Genestie C, Treilleux I, Croce S, et al.
Gynecol Oncol
. 2022 Apr;
165(3):637-641.
PMID: 35393217
Introduction: Since 2010, the network of rare malignant tumors of the ovary (TMRG) was developed to optimize the management of patients, also allowing a histological second opinion of rare ovarian...
18.
Nassif E, Blay J, Massard C, Dufresne A, Brahmi M, Cassier P, et al.
ESMO Open
. 2022 Mar;
7(2):100425.
PMID: 35255445
Background: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed...
19.
Francis K, Kim S, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, et al.
Ann Oncol
. 2022 Feb;
33(6):593-601.
PMID: 35219776
Background: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy. In the SOLO2...
20.
Vergote I, Gonzalez-Martin A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al.
Ann Oncol
. 2021 Dec;
33(3):276-287.
PMID: 34861371
Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR...